These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1453 related items for PubMed ID: 19445548

  • 1. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP, Keating GM.
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [Abstract] [Full Text] [Related]

  • 2. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP, Keating GM.
    CNS Drugs; 2010 Jan; 24(1):85-8. PubMed ID: 20030421
    [Abstract] [Full Text] [Related]

  • 3. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D, Plosker GL.
    Drugs; 2004 Jan; 64(2):205-22. PubMed ID: 14717619
    [Abstract] [Full Text] [Related]

  • 4. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.
    Encephale; 2005 Jan; 31(3):337-48. PubMed ID: 16142049
    [Abstract] [Full Text] [Related]

  • 5. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D, Plosker GL.
    CNS Drugs; 2004 Jan; 18(6):397-401. PubMed ID: 15089111
    [Abstract] [Full Text] [Related]

  • 6. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
    Prasad S, Steer C.
    Paediatr Drugs; 2008 Jan; 10(1):39-47. PubMed ID: 18162007
    [Abstract] [Full Text] [Related]

  • 7. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE, Kratochvil CJ.
    Drugs; 2010 Jan; 70(1):15-40. PubMed ID: 20030423
    [Abstract] [Full Text] [Related]

  • 8. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
    Gaillez C, Sorbara F, Perrin E.
    Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
    [Abstract] [Full Text] [Related]

  • 9. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.
    Christman AK, Fermo JD, Markowitz JS.
    Pharmacotherapy; 2004 Aug; 24(8):1020-36. PubMed ID: 15338851
    [Abstract] [Full Text] [Related]

  • 10. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 11. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 12. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP, Bettinger TL, Patel NC, Crismon ML.
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [Abstract] [Full Text] [Related]

  • 13. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH, Goa KL.
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [Abstract] [Full Text] [Related]

  • 14. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.
    Dell'Agnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A.
    CNS Drugs; 2009 Sep; 23(9):739-53. PubMed ID: 19689165
    [Abstract] [Full Text] [Related]

  • 15. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
    Hong J, Dilla T, Arellano J.
    BMC Psychiatry; 2009 Apr 14; 9():15. PubMed ID: 19366449
    [Abstract] [Full Text] [Related]

  • 16. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
    Corman SL, Fedutes BA, Culley CM.
    Am J Health Syst Pharm; 2004 Nov 15; 61(22):2391-9. PubMed ID: 15581262
    [Abstract] [Full Text] [Related]

  • 17. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb 15; 19(105):5-8. PubMed ID: 20455329
    [Abstract] [Full Text] [Related]

  • 18. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
    Reed VA, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, Coghill DR, Kryzhanovskaya LA, Savill NC.
    CNS Drugs; 2016 Jul 15; 30(7):603-28. PubMed ID: 27290715
    [Abstract] [Full Text] [Related]

  • 19. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
    Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J.
    J Am Acad Child Adolesc Psychiatry; 2007 Feb 15; 46(2):242-51. PubMed ID: 17242628
    [Abstract] [Full Text] [Related]

  • 20. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS.
    Value Health; 2008 Feb 15; 11(3):376-88. PubMed ID: 18489664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.